Revenue

12 Months Ended

Sep. 30, 2024

Revenue from Contract with Customer [Abstract]

Revenue

NOTE P – REVENUE

Trade receivables

Trade receivables are defined as receivables arising from contracts with customers and are recorded within the accounts receivable caption within the Consolidated Balance Sheets. Ashland’s trade receivables were $206 million and $288 million as of September 30, 2024 and September 30, 2023, respectively. See Note H for additional information on Ashland's program to sell certain receivables on a revolving basis to third party banks up to an aggregate purchase limit.

Disaggregation of revenue

Ashland disaggregates its revenue from contracts with customers by segment and geographical region, as Ashland believes these categories best depict how management reviews the financial performance of its operations for the twelve months ended September 30, 2024, 2023 and 2022. Ashland includes only U.S. and Canada in its North America designation and includes Europe, the Middle East and Africa in its Europe designation. See the following tables for details (Intersegment sales eliminations have been excluded. See Note Q for additional information.):

Sales by geography
(In millions)	2024		2023		2022
Life Sciences
North America	$	241	$	228	$	244
Europe		269		305		267
Asia Pacific		225		233		218
Latin America & other		75		103		86
	$	810	$	869	$	815
(In millions)	2024		2023		2022
Personal Care
North America	$	183	$	176	$	198
Europe		238		233		270
Asia Pacific		128		105		126
Latin America & other		85		84		84
	$	634	$	598	$	678
(In millions)	2024		2023		2022
Specialty Additives
North America	$	183	$	203	$	247
Europe		208		214		258
Asia Pacific		153		153		182
Latin America & other		28		30		32
	$	572	$	600	$	719
(In millions)	2024		2023		2022
Intermediates
North America	$	103	$	128	$	163
Europe		21		27		39
Asia Pacific		16		22		43
Latin America & other		4		8		11
	$	144	$	185	$	256

For fiscal 2024, Ashland had two product categories that represented 10% or greater of Ashland's total consolidated sales which were cellulosics representing 37% of total consolidated sales and polyvinylprrolidones (PVP) representing 23% of total consolidated sales.